Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Gross Profit (2016 - 2025)

Mimedx's Gross Profit history spans 15 years, with the latest figure at $99.0 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 30.32% year-over-year to $99.0 million; the TTM value through Dec 2025 reached $345.6 million, up 19.67%, while the annual FY2025 figure was $345.6 million, 19.67% up from the prior year.
  • Gross Profit for Q4 2025 was $99.0 million at Mimedx, up from $95.0 million in the prior quarter.
  • Across five years, Gross Profit topped out at $99.0 million in Q4 2025 and bottomed at $43.7 million in Q4 2021.
  • The 5-year median for Gross Profit is $67.3 million (2023), against an average of $66.2 million.
  • The largest annual shift saw Gross Profit dropped 24.28% in 2021 before it skyrocketed 38.22% in 2025.
  • A 5-year view of Gross Profit shows it stood at $43.7 million in 2021, then skyrocketed by 37.27% to $60.0 million in 2022, then increased by 21.64% to $73.0 million in 2023, then rose by 4.12% to $76.0 million in 2024, then skyrocketed by 30.32% to $99.0 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Gross Profit are $99.0 million (Q4 2025), $95.0 million (Q3 2025), and $79.9 million (Q2 2025).